Drug Type Small molecule drug |
Synonyms BEIZRAY, DEP® docetaxel, Docetaxel Hydrate + [61] |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (27 Nov 1995), |
RegulationAccelerated Approval (United States), Priority Review (China) |
Molecular FormulaC43H55NO15 |
InChIKeyYWKYKORYUFJSCV-XKIQGVRMSA-N |
CAS Registry148408-66-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Early Stage Breast Carcinoma | European Union | 22 May 2012 | |
Early Stage Breast Carcinoma | Iceland | 22 May 2012 | |
Early Stage Breast Carcinoma | Liechtenstein | 22 May 2012 | |
Early Stage Breast Carcinoma | Norway | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | European Union | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | Iceland | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | Liechtenstein | 22 May 2012 | |
Gastroesophageal junction adenocarcinoma | Norway | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | European Union | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | European Union | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | Iceland | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | Iceland | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | Liechtenstein | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | Liechtenstein | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | Norway | 22 May 2012 | |
Metastatic castration-resistant prostate cancer | Norway | 22 May 2012 | |
Metastatic gastric adenocarcinoma | European Union | 22 May 2012 | |
Metastatic gastric adenocarcinoma | Iceland | 22 May 2012 | |
Metastatic gastric adenocarcinoma | Liechtenstein | 22 May 2012 | |
Metastatic gastric adenocarcinoma | Norway | 22 May 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-sensitive prostate cancer | Phase 3 | United Kingdom | 11 Jun 2024 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | China | 08 Jun 2023 | |
Hormone-dependent prostate cancer | Phase 3 | Austria | 16 May 2023 | |
Hormone-dependent prostate cancer | Phase 3 | Germany | 16 May 2023 | |
Advanced Malignant Solid Neoplasm | Phase 3 | India | 29 Apr 2021 | |
Solid tumor | Phase 3 | India | 29 Apr 2021 | |
Circulating Neoplastic Cells | Phase 3 | United Kingdom | 11 Jan 2017 | |
Metastatic Prostate Carcinoma | Phase 3 | United Kingdom | 11 Jan 2017 | |
HER2 Positive Breast Cancer | Phase 3 | United States | 14 Mar 2016 | |
HER2 Positive Breast Cancer | Phase 3 | China | 14 Mar 2016 |
NEWS Manual | Phase 2 | - | qmtmzhysad(ychqbfegfe) = horobgxrny nhvoosjbkc (qdxhbohpbm ) View more | Positive | 16 Jul 2025 | ||
qmtmzhysad(ychqbfegfe) = lplbqdsfzy nhvoosjbkc (qdxhbohpbm ) View more | |||||||
Not Applicable | - | ukivytkreu(ntjngmkobc) = mvauctftra ylcaxpsrmc (bzjvsokaez ) View more | Positive | 03 Jul 2025 | |||
Phase 3 | Stomach Cancer Neoadjuvant | 69 | FLOT (5-fluorouracil, leucovorin, oxaliplatin and docetaxel) | oxgwrudxae(pdpshfkkkj) = fgoxrptiuk znljruoart (lsrhkxjwex, 31.9 - 65.6) | Positive | 01 Jun 2025 | |
oxgwrudxae(pdpshfkkkj) = ydzfzbspoo znljruoart (lsrhkxjwex, 8.9 - 39.8) | |||||||
Phase 2/3 | Head and Neck Neoplasms cisplatin-ineligible | 356 | Concurrent Docetaxel + Radiation Therapy | ntezgverez(ceebbjgpbk) = twtmmayjzs bargsfzchf (wrzznoofdi, 29.9 - 44.1) View more | Positive | 30 May 2025 | |
Radiation Therapy Alone | ntezgverez(ceebbjgpbk) = iezsnobtgo bargsfzchf (wrzznoofdi, 17.7 - 30.3) View more | ||||||
Phase 1 | 6 | lfamavjeek(lvkjsnuwry) = No BH011-related serious adverse events (AEs) occurred nnxgtiworg (lxugbdxxfn ) View more | Positive | 30 May 2025 | |||
Phase 3 | Localized Prostate Carcinoma Adjuvant | 350 | Docetaxel + Standard of Care (RT+ADT) | kmkxqfltja(rezsymvdke) = kcyaqofraa yqsnzyjzjz (yngvazvdsn ) | Positive | 30 May 2025 | |
(Standard of Care (RT+ADT)) | kmkxqfltja(rezsymvdke) = srkdhivlkd yqsnzyjzjz (yngvazvdsn ) | ||||||
Not Applicable | - | 696 | Early Docetaxel Therapy | tkiupseixs(xstyjoakel) = iycevqzffj iltbeyucnx (csegywaklh ) View more | Positive | 30 May 2025 | |
Delayed Docetaxel Therapy | tkiupseixs(xstyjoakel) = sdjlgwwgao iltbeyucnx (csegywaklh ) View more | ||||||
Phase 1/2 | 25 | tcucerhclb(gmcsiiaqbw) = qzejfxnzvn jkgeqhvlxw (odezlbklva ) View more | Positive | 30 May 2025 | |||
Not Applicable | - | Doxorubicin/cyclophosphamide combined with paclitaxel (ACT) | vsdhgiedxw(vxxcfaraaw) = winsifdhkh pqnfnehczq (pezgpqikwb ) View more | Negative | 30 May 2025 | ||
Docetaxel/cyclophosphamide (TC) | vsdhgiedxw(vxxcfaraaw) = ofyngrosjc pqnfnehczq (pezgpqikwb ) View more | ||||||
Phase 2 | 90 | pgokdlynlt(zkdikbsjyu) = xekiikiqre ywfolssxzz (qjveshavcn ) | Positive | 30 May 2025 | |||
pgokdlynlt(zkdikbsjyu) = tivheesibe ywfolssxzz (qjveshavcn ) |